[Association between CD24 polymorphism and genetic susceptibility to breast cancer: a case-control study]

To evaluate the association between CD24 polymorphism and genetic susceptibility to breast cancer in Chongqing women of Han nationality.

In the case-control study, single nucleotide polymorphism of CD24 (rs3838646 and rs52812045) was genotyped by Sequenom MassArray®iPLEX GOLD System in 170 patients with breast cancer and 178 healthy controls. Data were analyzed via t test, Chi-square test, and logistic regression analysis.

The distribution of CD24 rs3838646 genotype and allelotype had no significant difference between the patients with breast cancer and healthy controls (χ2=3.54, P=0.17; χ2=2.29, P=0.13). Stratified by menstruation status, premenopausal individuals carrying CD24 rs3838646 Del allele significantly reduced the risk (OR=0.51, 95% CI 0.26-1.00, P=0.0485) of breast cancer compared with the individuals carrying CD24 CA/CA genotype. The distribution of CD24 rs52812045 genotypes and allelotypes had no significant difference between the patients with breast cancer and healthy controls (χ2=5.37, P=0.07; χ2=3.05, P=0.08). Compared with C/C homozygotes, CD24 rs52812045 T/T homozygotes had a significantly reduced risk (OR=0.47, 95% CI 0.23-0.95; P=0.04) for breast cancer.

CD24 polymorphism may be a marker for susceptibility to breast cancer in Han population in southwestern China. CD24 polymorphisms may be associated with a reduced risk of breast cancer in Chinese population. Further studies are needed to confirm these findings.